Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-641: pembrolizumab plus enzalutamide versus placebo plus enzalutamide in metastatic castration-resistant prostate cancer
jRCT2080224920Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Pembrolizumab + enzalutamide with Placebo + enzalutamide (2 arms). Primary endpoints: Overall survival and Radiographic progression-free survival. Started Oct 2019; status: completed.
02
Drugs
pembrolizumabenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2080224920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224920.